Atea Pharmaceuticals Inc. Common Stock (AVIR)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Atea as a pre-revenue clinical biotech, not a conventional Graham bargain. Its lead bemnifosbuvir/ruzasvir regimen is in Phase 3 for hepatitis C, with AT-587 in Phase 1 for chronic HEV; 55 employees and no product sales mean the moat is unproven until approval and reimbursement. The reported record is a string of losses: net loss was $158.3M in FY2025, $168.4M in FY2024, and $136.0M in FY2023, while fiscal Q2 2026 (quarter ended 2026-06-30) lost $32.9M and fiscal Q1 2026 lost $45.4M. Trailing free cash flow was -$152.1M, a -45.6% FCF yield on the $333.7M market cap at the 2026-10-26 close. The balance sheet has no debt per D/E of 0.00, and FairStock's Altman Z-score is 4.33, but Piotroski is only 2/9 and ROE/ROCE are -58.14%/-36.72%. At $4.16, FairStock shows P/E -2.00 and P/B 1.64; with no earnings, valuation rests on pipeline probability, not current cash generation. The 52-week range of $2.87-$6.45 and low beta 0.28 suggest the market sees this as a binary clinical story. I would want a large margin of safety for trial failure and dilution risk; the FairStock score of 32/100 underscores how little current fundamentals support the price.

In plain English: Atea is a small clinical-stage drug developer working on oral antiviral treatments, mainly for hepatitis C. It has no product sales yet and has been losing money while using cash, so the underlying business looks weak on current numbers. At $4.16 a share on October 26, 2026, the price looks speculative rather than clearly cheap or fair based on today's profits and cash flow.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer